tnfi Search Results


tnfi  (Corrona LLC)
90
Corrona LLC tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi, supplied by Corrona LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi/pmc06525627-59-17-10
Average 90 stars, based on 1 article reviews
tnfi - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi treatment  (AbbVie Inc)
90
AbbVie Inc tnfi treatment
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi Treatment, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi+treatment/pm32213001-17598-0-43
Average 90 stars, based on 1 article reviews
tnfi treatment - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi therapy  (Corrona LLC)
90
Corrona LLC tnfi therapy
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi Therapy, supplied by Corrona LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi+therapy/pm25651481-242-13-48
Average 90 stars, based on 1 article reviews
tnfi therapy - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
non-tnfi  (Corrona LLC)
90
Corrona LLC non-tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Non Tnfi, supplied by Corrona LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/non+tnfi/pm28298374-76-138-219
Average 90 stars, based on 1 article reviews
non-tnfi - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi  (Celltrion inc)
90
Celltrion inc tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi, supplied by Celltrion inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi/pm23253920-70-2-1
Average 90 stars, based on 1 article reviews
tnfi - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi ada  (AbbVie Inc)
90
AbbVie Inc tnfi ada
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi Ada, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi+ada/pm40428231-53-12-14
Average 90 stars, based on 1 article reviews
tnfi ada - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi  (Wolters Kluwer Health)
86
Wolters Kluwer Health tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi/10__1097_slash_qad__0000000000002985-47-76-38
Average 86 stars, based on 1 article reviews
tnfi - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
tumornekrosefaktorinhibitoren (tnfi)  (Anwendung GmbH)
90
Anwendung GmbH tumornekrosefaktorinhibitoren (tnfi)
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tumornekrosefaktorinhibitoren (Tnfi), supplied by Anwendung GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tumornekrosefaktorinhibitoren++tnfi+/pm36757415-45-0-6
Average 90 stars, based on 1 article reviews
tumornekrosefaktorinhibitoren (tnfi) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi  (Kemper GmbH)
90
Kemper GmbH tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi, supplied by Kemper GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi/10__1002_slash_14651858__cd013715__pub2-1263-5-27
Average 90 stars, based on 1 article reviews
tnfi - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi  (Anwendung GmbH)
90
Anwendung GmbH tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi, supplied by Anwendung GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi/pm35113204-134-5-14
Average 90 stars, based on 1 article reviews
tnfi - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi  (Regeneron inc)
90
Regeneron inc tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi, supplied by Regeneron inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi/10__1007_slash_s40274___017___4478___6-8-37-66
Average 90 stars, based on 1 article reviews
tnfi - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
tnfi  (Optum Inc)
86
Optum Inc tnfi
Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic <t>(TNFi</t> naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, <t>n=32).</t> <t>PsA,</t> psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.
Tnfi, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tnfi/tnfi/pmc09117457-272-2-0
Average 86 stars, based on 1 article reviews
tnfi - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic (TNFi naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, n=32). PsA, psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.

Journal: RMD Open

Article Title: Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry

doi: 10.1136/rmdopen-2018-000880

Figure Lengend Snippet: Patient disposition. The total follow-up period included 579.2 person-years, with a mean (SD) follow-up of 21.9 (9.6) months and median (IQR) follow-up of 23.0 (15.0) months. Patients included in the discontinued groups were those who switched to a new biologic (TNFi naive, n=33; TNFi experienced, n=48) or who discontinued without switching (TNFi naive, n=42; TNFi experienced, n=32). PsA, psoriatic arthritis; SpA, spondyloarthritis; TNFi, tumour necrosis factor inhibitor.

Article Snippet: All patients aged ≥18 years with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry who initiated a TNFi (index therapy) between March 2013 and January 2017 and had ≥1 follow-up visit were included.

Techniques:

Baseline demographics and clinical characteristics of TNFi-naive and TNFi-experienced patients with PsA overall and in those who continued versus discontinued their index TNFi by the first follow-up visit

Journal: RMD Open

Article Title: Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry

doi: 10.1136/rmdopen-2018-000880

Figure Lengend Snippet: Baseline demographics and clinical characteristics of TNFi-naive and TNFi-experienced patients with PsA overall and in those who continued versus discontinued their index TNFi by the first follow-up visit

Article Snippet: All patients aged ≥18 years with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry who initiated a TNFi (index therapy) between March 2013 and January 2017 and had ≥1 follow-up visit were included.

Techniques: Infection

Baseline disease activity and patient-reported outcomes in TNFi-naive and TNFi-experienced patients with PsA overall and in those who continued versus discontinued their index TNFi by the first follow-up visit

Journal: RMD Open

Article Title: Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry

doi: 10.1136/rmdopen-2018-000880

Figure Lengend Snippet: Baseline disease activity and patient-reported outcomes in TNFi-naive and TNFi-experienced patients with PsA overall and in those who continued versus discontinued their index TNFi by the first follow-up visit

Article Snippet: All patients aged ≥18 years with PsA enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry who initiated a TNFi (index therapy) between March 2013 and January 2017 and had ≥1 follow-up visit were included.

Techniques: Activity Assay